365 related articles for article (PubMed ID: 20631361)
21. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
[TBL] [Abstract][Full Text] [Related]
22. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma.
Hagtvedt T; Seierstad T; Lund KV; Løndalen AM; Bogsrud TV; Smith HJ; Geier OM; Holte H; Aaløkken TM
Acta Radiol; 2015 Feb; 56(2):152-8. PubMed ID: 24585944
[TBL] [Abstract][Full Text] [Related]
23. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].
Bestic JM; Peterson JJ; Bancroft LW
Radiographics; 2009; 29(5):1487-500. PubMed ID: 19755607
[TBL] [Abstract][Full Text] [Related]
24. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
[TBL] [Abstract][Full Text] [Related]
26. Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT.
Hanrahan CJ; Christensen CR; Crim JR
Radiographics; 2010 Jan; 30(1):127-42. PubMed ID: 20083590
[TBL] [Abstract][Full Text] [Related]
27. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake.
Kostakoglu L; Hardoff R; Mirtcheva R; Goldsmith SJ
Radiographics; 2004; 24(5):1411-31. PubMed ID: 15371617
[TBL] [Abstract][Full Text] [Related]
28. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
29. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
30. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
31. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer.
Qu X; Huang X; Yan W; Wu L; Dai K
Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
33. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
[TBL] [Abstract][Full Text] [Related]
34. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
35. 18F-FDG PET and PET/CT in Burkitt's lymphoma.
Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA
Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248
[TBL] [Abstract][Full Text] [Related]
36. 18F-fluorodeoxyglucose-positron emission tomography in the staging of malignant lymphoma compared with CT and 67Ga scan.
Hong SP; Hahn JS; Lee JD; Bae SW; Youn MJ
Yonsei Med J; 2003 Oct; 44(5):779-86. PubMed ID: 14584092
[TBL] [Abstract][Full Text] [Related]
37. The role of PET and PET/CT in managing the care of lymphoma patients.
Evans WC; Gilmore D; English J
J Nucl Med Technol; 2011 Sep; 39(3):190-4. PubMed ID: 21795369
[TBL] [Abstract][Full Text] [Related]
38. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET.
Subhas N; Patel PV; Pannu HK; Jacene HA; Fishman EK; Wahl RL
Radiographics; 2005; 25(4):1031-43. PubMed ID: 16009822
[TBL] [Abstract][Full Text] [Related]
39. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in penile cancer.
Zhang S; Li W; Liang F
Oncotarget; 2016 Jul; 7(30):48600-48606. PubMed ID: 27203206
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study.
Fruchart C; Reman O; Le Stang N; Musafiri D; Cheze S; Macro M; Switsers O; Aide N; Liegard M; Levaltier X; Peny AM; Leporrier M; Bardet S
Leuk Lymphoma; 2006 Dec; 47(12):2547-57. PubMed ID: 17169799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
